The role of cardiac mitochondrial energetics in cardiac arrhythmias and SUDEP

心脏线粒体能量学在心律失常和 SUDEP 中的作用

基本信息

  • 批准号:
    10405287
  • 负责人:
  • 金额:
    $ 5.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary Dravet Syndrome (DS) is a catastrophic pediatric epilepsy that largely arises from loss-of-function mutations in sodium channel genes. Overlapping neuronal and cardiac expression patterns of mutant sodium channels are proposed to underlie the pathophysiology of a number of genetic diseases that exhibit both epileptic and cardiac phenotypes. The risk of sudden death in epilepsy patients is twenty four times greater than the general population. Despite advances in recent years to understand the mechanisms of Sudden Unexpected Death in Epilepsy (SUDEP), it has remained elusive. Proposed mechanisms of SUDEP have implicated seizure-induced apnea, pulmonary edema, dysregulation of cerebral circulation, autonomic dysfunction, or cardiac arrhythmias. Besides being the powerhouse of the cell, the mitochondria is responsible for long term ionic balance in the cell and compromised mitochondrial function may precede cardiac arrhythmias and epileptic events. Our central hypothesis is that compromised mitochondrial energetics and ionic homeostasis predisposes DS patients to cardiac arrhythmias, seizures, and SUDEP-like events. The parent project seeks to uncover novel mechanisms by which cardiac excitability is altered due to compromised mitochondrial energetics in Dravet Syndrome (DS) models, a form of epilepsy with a high incidence of SUDEP. This supplement will focus on mitochondria mechanisms of epileptogenesis in DS. The significance of this project is that it fills a major void in understanding the mechanism of SUDEP in DS and results from the proposed experiments have the potential to lead to new therapeutic treatments in DS. While this grant focuses on the role of DS mutations, it is our hope that these results may be applicable to other genetic and non-genetic epilepsies that will be the focus of future projects. The proposed studies will provide valuable insight to the field and may lead to the discovery of several potential therapeutic targets for DS. The mitochondria represent an ideal target to investigate, as there is growing interest in the mitochondrial mechanisms of arrhythmogenesis and novel drugs may soon be available to test in epilepsy models.
项目摘要 Dravet综合征(DS)是一种严重的儿童癫痫,主要由功能丧失引起 钠离子通道基因突变。突变体的重叠神经和心脏表达模式 钠通道被认为是许多遗传疾病的病理生理学基础, 表现出癫痫和心脏病的表型。癫痫患者猝死的风险为20 比一般人多四倍。尽管近年来在了解 癫痫猝死(Sudden Unexpected Death in Epilepsy,SUDEP)的发病机制至今仍不清楚。提出 SUDEP的机制涉及呼吸暂停、肺水肿、呼吸系统功能失调、 脑循环、自主神经功能障碍或心律失常。除了作为一个发电站, 线粒体负责细胞内的长期离子平衡, 线粒体功能可能先于心律失常和癫痫事件。我们的核心假设是 损害线粒体能量和离子稳态使DS患者易患心脏病, 心律失常、癫痫发作和SUDEP样事件。母项目旨在揭示新的机制, 由于Dravet的线粒体能量学受损, 综合征(DS)模型,一种具有高SUDEP发生率的癫痫形式。本附录将重点介绍 DS癫痫发生的线粒体机制这个项目的意义在于它填补了一个主要的 在理解DS中SUDEP的机制方面存在空白,并且从所提出的实验中得到的结果 可能导致DS的新治疗方法。虽然这项赠款的重点是DS的作用 突变,我们希望这些结果可能适用于其他遗传和非遗传 癫痫病将是未来项目的重点。拟议的研究将提供宝贵的见解, 该领域的研究,并可能导致发现几个潜在的治疗目标的DS。线粒体 代表了一个理想的研究目标,因为人们对线粒体机制越来越感兴趣, 癫痫发生和新药可能很快就可以在癫痫模型中进行测试。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Teriflunomide treatment exacerbates cardiac ischemia reperfusion injury in isolated rat hearts.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chad Frasier其他文献

Chad Frasier的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chad Frasier', 18)}}的其他基金

The role of cardiac mitochondrial energetics in cardiac arrhythmias and SUDEP
心脏线粒体能量学在心律失常和 SUDEP 中的作用
  • 批准号:
    10057795
  • 财政年份:
    2020
  • 资助金额:
    $ 5.9万
  • 项目类别:

相似海外基金

DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
  • 批准号:
    495592
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
Preliminary Study to Establish Heavy Ion Ablation Therapy for Lethal Ventricular Arrhythmia
重离子消融治疗致死性室性心律失常的初步研究
  • 批准号:
    23K14885
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Arrhythmia Mechanisms Modulated by Intercalated Disc Extracellular Nanodomains
闰盘细胞外纳米结构域调节心律失常的机制
  • 批准号:
    10668025
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
Development of a next-generation telemonitoring system for prognostic prediction of the onset of heart failure and arrhythmia
开发下一代远程监测系统,用于心力衰竭和心律失常发作的预后预测
  • 批准号:
    23K09597
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The role of inflammation in the pathogenesis of atrial fibrillation: Implications for atrial remodeling pathophysiology and for early atrial arrhythmia recurrences following radiofrequency ablation and pulsed field ablation
炎症在心房颤动发病机制中的作用:对心房重塑病理生理学以及射频消融和脉冲场消融后早期房性心律失常复发的影响
  • 批准号:
    514892030
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
    WBP Fellowship
Improved arrhythmia ablation via MR-guided robotic catheterization and multimodal clinician feedback
通过 MR 引导的机器人导管插入术和多模式临床医生反馈改善心律失常消融
  • 批准号:
    10638497
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
Prototype development and validation of soft robotic sensor arrays for mapping cardiac arrhythmia
用于绘制心律失常的软机器人传感器阵列的原型开发和验证
  • 批准号:
    10722857
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
A novel regulator of Ca2+ homeostasis and arrhythmia susceptibility
Ca2 稳态和心律失常易感性的新型调节剂
  • 批准号:
    10724935
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
Novel Stellate Ganglia Chemo-ablation Approach to Treat Cardiac Arrhythmia and Cardiac Remodeling in Heart Failure
新型星状神经节化疗消融方法治疗心律失常和心力衰竭心脏重塑
  • 批准号:
    10727929
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了